组合型非生物型人工肝治疗成人慢加急性肝衰竭的研究进展  

Research advances in combined non-bioartificial liver in treatment of acute-on-chronic liver failure in adults

作　　者：王璐 许文雄[1] 彭亮[1] WANG Lu;XU Wenxiong;PENG Liang(Department of Infectious Diseases,The Third Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510635,China)

机构地区：[1]中山大学附属第三医院感染科,广州510635

出　　处：《临床肝胆病杂志》2022年第7期1662-1666,共5页Journal of Clinical Hepatology

基　　金：“艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项“十三五”课题(2018ZX10302204-002);国家自然科学基金面上项目(81873572,82070611);中山大学5010临床研究项目(2020007);中山大学附属第三医院“五个五”工程项目(K00006)。

摘　　要：慢加急性肝衰竭是临床常见的严重肝病症候群,短期病死率极高。非生物型人工肝是治疗慢加急性肝衰竭的有效手段之一。面对血源紧张、治疗理念的改变现状,非生物型人工肝的联合治疗可以做到优势互补,更好的满足临床需求。本文重点介绍组合型非生物型人工肝治疗慢加急性肝衰竭的临床应用及研究进展,并对其现存问题进行总结与展望。Acute-on-chronic liver failure(ACLF)is a common syndrome of severe liver diseases in clinical practice and has an extremely high short-term mortality rate.Non-bioartificial liver(NBAL)therapy is one of the effective treatment methods for patients with ACLF.In face of the current status of blood supply shortage and changes of treatment concepts,combined NBAL therapy can achieve mutual complementarity and better meet the clinical needs.This article focuses on the clinical application of NBAL in the treatment of ACLF and related research advances and summarizes existing problems and future prospects.

关 键 词：慢加急性肝功能衰竭 肝 人工 治疗学 

分 类 号：R575.3[医药卫生—消化系统]